Abstract OT1-07-06: Phase 1/2 first-in-human study of U3-1402, an anti-human epidermal growth factor receptor 3 (HER3) antibody-drug conjugate, in HER3-expressing advanced/unresectable or metastatic breast cancer, including those with triple negative breast cancer (TNBC) or HER3-low disease
Year: 2020
Type: conference-abstract
Source: Cancer Research
Authors: Ian Krop, Norikazu Masuda, Takahiro Kogawa, Shunji Takahashi, Kan Yonemori, Kenichi Inoue, Takahiro Nakayama, Yutaka Yamamoto, Ricardo Alvarez, Tatsuya Toyama, Akihiko Osaki, Masato Takahashi, Joyce O'Shaughnessy, Yasuaki Sagara, Shigehira Saji, Virginia Kaklamani, Sun Young Oh, William Gradishar, Barbara Haley, Tsutomu Iwasa, Tiffany Traina, Naoto Ueno, Steve Isakoff, Shoichi Ohwada, Yoshimi Tanaka, Sabeen Mekan, Hiroshi Onuma, Om Sharma, Hiroji Iwata
Institutions: Dana-Farber Cancer Institute, Osaka National Hospital, National Cancer Center Hospital East, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, National Cancer Centre Japan, Saitama Cancer Center, Osaka International Cancer Institute, Kumamoto University Hospital, Cancer Treatment Centers of America, Nagoya City University, Saitama Medical University, Sapporo National Hospital, Sagara Hospital, Fukushima Medical University Hospital, The University of Texas at San Antonio Health Science Center, Albert Einstein College of Medicine, Montefiore Einstein Comprehensive Cancer Center, Northwestern University, The University of Texas Southwestern Medical Center, Kindai University Hospital, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, Daiichi-Sankyo (Japan), Daiichi Sankyo (United States), Aichi Cancer Center
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3013875383